Lymphoma

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

The William L. McGuire Lecture Award will be presented to Olufunmilayo Olopade, MD, FAACR, at San Antonio Breast Cancer Symposium this month.

The FDA granted orphan drug designation to nanatinostat and valganciclovir for treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma not otherwise specified.

Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous group of diseases for which individualized care is crucial, according to a speaker at Chemotherapy Foundation Symposium.

The FDA granted fast track designation to EZM0414 for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

Management of cancer therapies in the era of COVID-19 infection and vaccination requires careful consideration of both disease and patient characteristics, according to members of a crossfire panel at Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.

The FDA granted priority review to parsaclisib for two lymphoma indications.

Three individuals have been elected to American Society of Hematology’s executive committee.